Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2020-10-22 Capital/Financing Update
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent erhåller milstolpsbetalning på 2 miljoner euro från Daiichi Sankyo
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 22, 2020, announcing that BioInvent International AB will receive a milestone payment of 2 million euros from Daiichi Sankyo related to the initiation of a global Phase I clinical study for an anti-GARP antibody (DS-1055). This content describes a specific corporate event (milestone achievement tied to financing/collaboration progress) and is structured as a news announcement, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It fits best under Capital/Financing Update (CAP) as it details a cash inflow resulting from a partnership milestone, or potentially Regulatory Filings (RNS) if viewed as a general corporate announcement. Given the direct mention of receiving a payment tied to clinical progress, 'CAP' is a strong fit, but since it's a general press release about a corporate event rather than a formal financing document, 'RNS' (Regulatory Filings/General Announcement) is often the appropriate category for non-standard press releases detailing partnership milestones, especially when the primary focus is the announcement itself rather than the financial structure change. However, since the core event is receiving capital based on a development milestone, 'CAP' is more specific than the general 'RNS' fallback. Let's re-evaluate against the definitions. It is not an ER, IR, or 10-K. It is a specific announcement about a financial event derived from a collaboration. 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' Receiving a milestone payment falls under financing activities. I will classify it as CAP.
2020-10-22 Swedish
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement dated August 31, 2020, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). The core content explicitly states the total number of shares and votes, attributing the change to a recent rights issue (nyemission). This directly relates to changes in the company's capital structure (share count). This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Given the specific nature of reporting changes in the total outstanding share count following a capital event, SHA is the most precise classification.
2020-08-31 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and the first half of 2020 for BioInvent. It includes detailed financial statements (net sales, profit/loss, cash flow), management's discussion and analysis of business trends, pipeline updates, and clinical program status. It is not a mere announcement (RPA) or a short release, but a substantive interim report containing actual financial data and analysis. Q2 2020
2020-08-27 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and the first half of 2020. It includes specific financial data (net sales, loss after tax, cash flow, liquid funds), detailed management commentary on business operations, clinical trial progress, and pipeline updates. It is not a mere announcement (RPA) or a short earnings release (ER), as it provides substantive financial analysis and operational details consistent with an interim/quarterly report. H1 2020
2020-08-27 English
BioInvent’s repair rights issue of approximately SEK 139 million was heavily oversubscribed
Capital/Financing Update Classification · 99% confidence The document is explicitly titled as a "PRESS RELEASE" dated August 5, 2020, announcing that BioInvent's "repair rights issue of approximately SEK 139 million was heavily oversubscribed." The content details the subscription results, the proceeds raised, and the intended use of the funds. This clearly relates to a corporate financing activity, specifically an equity issuance (Rights Issue). This aligns directly with the definition for Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), but the primary subject is the capital raise itself.
2020-08-05 English
BioInvents kompensationsemission om cirka 139 MSEK var kraftigt övertecknad
Capital/Financing Update Classification · 99% confidence The document is a press release dated August 5, 2020, titled "BioInvent's compensation issue of approximately SEK 139 million was heavily oversubscribed." The text details the results of a rights issue (Företrädesemissionen), confirming that all new shares were subscribed, and specifies the amount raised (approx. SEK 139 million). It discusses the use of proceeds (clinical development) and the resulting increase in share capital. This content directly relates to a company's fundraising and capital structure change. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (11,840 chars), confirming it is the primary announcement, not just a brief RPA.
2020-08-05 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.